Menu
Back to User profile » Mr Alan A Martin
Papers published by Mr Alan A Martin:
Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
Kendall R, Martin AA, Shah D, Shukla S, Compton C, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1815-1825
Published Date: 21 August 2023
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
Paly VF, Vallejo-Aparicio LA, Martin A, Izquierdo JL, Riesco JA, Soler-Cataluña JJ, Abreu C, Biswas C, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:3097-3109
Published Date: 16 December 2022
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
Halpin DM, Kendall R, Shukla S, Martin A, Shah D, Midwinter D, Beeh KM, Kocks JWH, Jones PW, Compton C, Risebrough NA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2745-2755
Published Date: 25 October 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, Martinez FJ, Criner GJ, Martin N, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1633-1642
Published Date: 25 July 2022
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
Shukla S, Shah D, Martin A, Risebrough NA, Kendall R, Vogelmeier CF, Boucot I, Tombs L, Bjermer L, Jones PW, Kerwin E, Compton C, Maltais F, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:3105-3118
Published Date: 13 November 2021
Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective
Schroeder M, Benjamin N, Atienza L, Biswas C, Martin A, Whalen JD, Izquierdo Alonso JL, Riesco Miranda JA, Soler-Cataluña JJ, Huerta A, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1621-1632
Published Date: 10 July 2020
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
Ismaila AS, Risebrough N, Schroeder M, Shah D, Martin A, Goodall EC, Ndirangu K, Criner G, Dransfield M, Halpin DMG, Han MK, Lomas DA
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2681-2695
Published Date: 29 November 2019
Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V
Diabetes, Metabolic Syndrome and Obesity 2017, 10:403-412
Published Date: 29 September 2017
An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
Martin AA, Parks D
Diabetes, Metabolic Syndrome and Obesity 2016, 9:163-168
Published Date: 19 May 2016